Laurel Wealth Advisors LLC Has $382,000 Position in Pfizer Inc. (NYSE:PFE)

Laurel Wealth Advisors LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 25.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,266 shares of the biopharmaceutical company’s stock after selling 4,575 shares during the period. Laurel Wealth Advisors LLC’s holdings in Pfizer were worth $382,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of PFE. Briaud Financial Planning Inc bought a new position in shares of Pfizer during the 3rd quarter worth about $30,000. Mizuho Securities Co. Ltd. bought a new position in shares of Pfizer during the 3rd quarter worth about $34,000. VisionPoint Advisory Group LLC boosted its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC boosted its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer during the 4th quarter worth about $36,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.14 during mid-day trading on Friday, hitting $25.40. 46,526,457 shares of the stock were exchanged, compared to its average volume of 34,120,812. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a 50-day simple moving average of $26.96 and a 200 day simple moving average of $28.36. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a market capitalization of $143.83 billion, a P/E ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter last year, the firm earned $1.14 EPS. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.61%. Pfizer’s payout ratio is currently 466.67%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.